Otsuka in €100m+ Japan deal for Lundbeck's nalmefene
This article was originally published in Scrip
Executive Summary
In an expansion of their November 2011 strategic alliance for CNS products, Otsuka Pharmaceutical and Lundbeck are to collaborate for the development and commercialization in Japan of Lundbeck's alcohol dependency drug nalmefene.